Having trouble accessing articles? Reset your cache.

Dendritic cell dragnet

The inability of peripheral immune cells to penetrate the CNS protects the brain against inflammation but has thwarted efforts to stimulate immunity against brain cancer antigens. Now a team at Cedars-Sinai Medical Center has devised a way around this barrier using an immunomodulatory peptide called FMS-like tyrosine kinase 3 ligand.1

The finding is serendipitous for Celldex Therapeutics Inc., which in-licensed FMS-like tyrosine kinase 3 ligand (FLT3LG; FLT3L) from Amgen Inc. last year in hopes of using the molecule to mobilize myeloid progenitor cells.

The brain, the testes and parts of the eye are thought

Read the full 928 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers